Growing evidences revealed that DDX5 is significantly associated with tumorigenesis.1, 2 It is overexpressed in colorectal3, gastric4, breast, and prostate tumours and is associated with tumour progression.5, 6 In addition, it acts as a coactivator of several transcription factors, including β‐catenin, p53, oestrogen receptor alpha, AKT signalling pathway, c‐Myc, and androgen receptors.7, 8 Recent study also showed that DDX5 is significantly elevated in gastric cancer and co‐excited the mTOR signalling pathway to enhance the growth of gastric cancer cells. Here, AKT1 is linked to gastric cancer.